A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma

Metastatic Hepatocellular Carcinoma

Monoclonal Antibody ◽

Phase I ◽

Dose Escalation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

414 POSTER A phase I, open-label, dose escalation study of the humanized monoclonal antibody (HuMAb) TRC093, an inhibitor of angiogenesis that binds to cleaved collagen, in patients with locally advanced or metastatic solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72348-6 ◽

2008 ◽

Vol 6 (12) ◽

pp. 130 ◽

Cited By ~ 1

Author(s):

M.S. Gordon ◽

L.S. Rosen ◽

F. Robert ◽

D.S. Mendelson ◽

D. Kleinzweig ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

Humanized Monoclonal Antibody ◽

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Cancer Medicine ◽

10.1002/cam4.1140 ◽

2017 ◽

Vol 6 (8) ◽

pp. 1904-1914 ◽

Cited By ~ 11

Author(s):

Benjamin Izar ◽

William Sharfman ◽

F. Stephen Hodi ◽

Donald Lawrence ◽

Keith T. Flaherty ◽

...

Keyword(s):

Phase I ◽

Metastatic Melanoma ◽

Dose Escalation ◽

Braf Mutation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

Mutation Status ◽

An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(16)32646-6 ◽

2016 ◽

Vol 69 ◽

pp. S22 ◽

Cited By ~ 1

Author(s):

G.K. Abou-Alfa ◽

J.H. Yoon ◽

M. Modiano ◽

B.Y. Ryoo ◽

T. Yau ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Advanced Hepatocellular Carcinoma ◽

Open Label ◽

Dose Escalation Study

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

BMC Cancer ◽

10.1186/s12885-017-3641-6 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 8

Author(s):

Kerry Lynn Reynolds ◽

Philippe L. Bedard ◽

Se-Hoon Lee ◽

Chia-Chi Lin ◽

Josep Tabernero ◽

...

Keyword(s):

Gastric Cancer ◽

Monoclonal Antibody ◽

Squamous Cell Carcinoma ◽

Phase I ◽

Dose Escalation ◽

Advanced Squamous Cell Carcinoma ◽

Open Label ◽

Dose Escalation Study ◽

Carcinoma Of The Esophagus ◽

Faculty of 1000 evaluation for CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718099088.793483839 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Phase I ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY

Journal of Hepatology ◽

10.1016/s0168-8278(12)61422-6 ◽

2012 ◽

Vol 56 ◽

pp. S555

Author(s):

S.M. Stemmer ◽

O. Benjaminov ◽

G. Medalia ◽

N.B. Ciuraru ◽

M.H. Silverman ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-0845 ◽

2021 ◽

pp. clincanres.0845.2021

Author(s):

Adi Diab ◽

Omid Hamid ◽

John A Thompson ◽

Willeke Ros ◽

Ferry A.L.M. Eskens ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/s0360-3016(02)03557-5 ◽

2002 ◽

Vol 54 (2) ◽

pp. 288 ◽

Cited By ~ 2

Author(s):

A Nabid ◽

P Ganguly ◽

V Venkatesan ◽

K Schneider ◽

D Sicheri ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Head And Neck ◽

Squamous Cell ◽

Dose Escalation ◽

Squamous Cell Cancer ◽

Cell Cancer ◽

Locally Advanced ◽

Dose Escalation Study ◽

Humanized Monoclonal Antibody

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72345-0 ◽

2008 ◽

Vol 6 (12) ◽

pp. 129 ◽

Cited By ~ 11

Author(s):

R. Salgia ◽

A. Peterson ◽

S. Eppler ◽

W. Yu ◽

B. Polite ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Dose Escalation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma

The Oncologist ◽

10.1634/theoncologist.2018-0838 ◽

2018 ◽

Vol 24 (6) ◽

pp. 747 ◽

Cited By ~ 14

Author(s):

Imane El Dika ◽

Ho Yeong Lim ◽

Wei Peng Yong ◽

Chia‐Chi Lin ◽

Jung‐Hwan Yoon ◽

...

Keyword(s):

Antitumor Activity ◽

Phase I ◽

Phase Ii ◽

Dose Escalation ◽

Advanced Hepatocellular Carcinoma ◽

Open Label ◽

Dose Escalation Study ◽

Multicenter Phase ◽

Expansion Cohort